<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B739936-E847-4D0C-8C2A-AE0C504D9F9A"><gtr:id>0B739936-E847-4D0C-8C2A-AE0C504D9F9A</gtr:id><gtr:name>Lausanne University</gtr:name><gtr:address><gtr:line1>Lausanne University</gtr:line1><gtr:line2>Dorigny</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/677061D0-41C5-458F-9708-32A56EC6D259"><gtr:id>677061D0-41C5-458F-9708-32A56EC6D259</gtr:id><gtr:name>Georgetown University</gtr:name><gtr:address><gtr:line1>37th and O Street, NW</gtr:line1><gtr:line4>Washington</gtr:line4><gtr:line5>DC 20057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/21AC01C5-7758-462E-8E2C-FEF0958FFF5A"><gtr:id>21AC01C5-7758-462E-8E2C-FEF0958FFF5A</gtr:id><gtr:name>BioArctic Neuroscience</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68FB3A84-29CE-4F10-B27B-1482AD81759C"><gtr:id>68FB3A84-29CE-4F10-B27B-1482AD81759C</gtr:id><gtr:name>Beatson Institute for Cancer Research</gtr:name><gtr:address><gtr:line1>Garscube Estate</gtr:line1><gtr:line2>Switchback Road, Bearsden</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G61 1BD</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/42C4AB31-4EFF-4C22-8F28-B1827BC2978C"><gtr:id>42C4AB31-4EFF-4C22-8F28-B1827BC2978C</gtr:id><gtr:name>Laval University</gtr:name><gtr:address><gtr:line1>Universite Laval</gtr:line1><gtr:line2>Sainte-Foy</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BEDAD782-6F89-4702-A460-9860075C45A9"><gtr:id>BEDAD782-6F89-4702-A460-9860075C45A9</gtr:id><gtr:name>DiscoveRx</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C23583E4-9B58-426B-95E0-C0D6088DCAA9"><gtr:id>C23583E4-9B58-426B-95E0-C0D6088DCAA9</gtr:id><gtr:name>Intellect Neurosciences, Inc.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8991DCB7-8024-49ED-83B7-E6761C627155"><gtr:id>8991DCB7-8024-49ED-83B7-E6761C627155</gtr:id><gtr:name>MRC Technology MRCT</gtr:name><gtr:address><gtr:line1>Lynton House</gtr:line1><gtr:postCode>WC1H 9LT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8991DCB7-8024-49ED-83B7-E6761C627155"><gtr:id>8991DCB7-8024-49ED-83B7-E6761C627155</gtr:id><gtr:name>MRC Technology MRCT</gtr:name><gtr:address><gtr:line1>Lynton House</gtr:line1><gtr:postCode>WC1H 9LT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B739936-E847-4D0C-8C2A-AE0C504D9F9A"><gtr:id>0B739936-E847-4D0C-8C2A-AE0C504D9F9A</gtr:id><gtr:name>Lausanne University</gtr:name><gtr:address><gtr:line1>Lausanne University</gtr:line1><gtr:line2>Dorigny</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/677061D0-41C5-458F-9708-32A56EC6D259"><gtr:id>677061D0-41C5-458F-9708-32A56EC6D259</gtr:id><gtr:name>Georgetown University</gtr:name><gtr:address><gtr:line1>37th and O Street, NW</gtr:line1><gtr:line4>Washington</gtr:line4><gtr:line5>DC 20057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/21AC01C5-7758-462E-8E2C-FEF0958FFF5A"><gtr:id>21AC01C5-7758-462E-8E2C-FEF0958FFF5A</gtr:id><gtr:name>BioArctic Neuroscience</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68FB3A84-29CE-4F10-B27B-1482AD81759C"><gtr:id>68FB3A84-29CE-4F10-B27B-1482AD81759C</gtr:id><gtr:name>Beatson Institute for Cancer Research</gtr:name><gtr:address><gtr:line1>Garscube Estate</gtr:line1><gtr:line2>Switchback Road, Bearsden</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G61 1BD</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42C4AB31-4EFF-4C22-8F28-B1827BC2978C"><gtr:id>42C4AB31-4EFF-4C22-8F28-B1827BC2978C</gtr:id><gtr:name>Laval University</gtr:name><gtr:address><gtr:line1>Universite Laval</gtr:line1><gtr:line2>Sainte-Foy</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEDAD782-6F89-4702-A460-9860075C45A9"><gtr:id>BEDAD782-6F89-4702-A460-9860075C45A9</gtr:id><gtr:name>DiscoveRx</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C23583E4-9B58-426B-95E0-C0D6088DCAA9"><gtr:id>C23583E4-9B58-426B-95E0-C0D6088DCAA9</gtr:id><gtr:name>Intellect Neurosciences, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4830774E-B06D-4FE1-99C9-69516BF67A35"><gtr:id>4830774E-B06D-4FE1-99C9-69516BF67A35</gtr:id><gtr:firstName>Justin</gtr:firstName><gtr:surname>Bryans</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1000806"><gtr:id>B881A1BC-A284-46A7-AD20-7CE3C5C25DB8</gtr:id><gtr:title>Expansion of MRCTs Drug Discovery Group (DDG)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1000806</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>To expand and enhance MRCTs successful early stage drug discovery resource, in order to provide capacity to engage effectively with the MRC extramural programme in drug (and biological) development funded through the MRCs Developmental Pathway Funding Scheme (DPFS).</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>5054000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aberdeen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CTLA4</gtr:description><gtr:id>D05AEE72-79F7-49C1-99B3-BB68AECCCF35</gtr:id><gtr:impact>Robust assay</gtr:impact><gtr:outcomeId>p6n5utEpq8d-1</gtr:outcomeId><gtr:partnerContribution>Provision of reagents</gtr:partnerContribution><gtr:piContribution>Assay development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>IL17BR</gtr:description><gtr:id>A71B27A1-8D88-4C99-9ECD-ED5F1A06479E</gtr:id><gtr:impact>Generation of a potent antibody plus supporting in vivo data for partnering</gtr:impact><gtr:outcomeId>5461d4f5ec2ef3.53709536-1</gtr:outcomeId><gtr:partnerContribution>Animal models and biology expertise</gtr:partnerContribution><gtr:piContribution>Humanisation and affinity maturation of a potent antibody</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>VCAM-1</gtr:description><gtr:id>67784D01-D053-4A62-B6B2-09FB85A7EC61</gtr:id><gtr:impact>Successful DPFS application</gtr:impact><gtr:outcomeId>qUPrXNAdT6T-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise and assays</gtr:partnerContribution><gtr:piContribution>Antibody generation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>TPL2</gtr:description><gtr:id>9773F351-4EFE-4CD9-8BFF-F37290A7F01B</gtr:id><gtr:impact>Development of a novel screen protocol</gtr:impact><gtr:outcomeId>5461d3b9689e55.92350946-1</gtr:outcomeId><gtr:partnerContribution>Biology and reagents</gtr:partnerContribution><gtr:piContribution>Assay development and screening</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BioArctic Neuroscience</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Mouse hybridomas</gtr:description><gtr:id>C46BEC6A-6EA6-42F8-A444-74EE2FE8AA4D</gtr:id><gtr:impact>Antibodies raised and humanised</gtr:impact><gtr:outcomeId>hF4b6wuqopi-1</gtr:outcomeId><gtr:piContribution>Raising and humanisation of mouse antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>PfCDPK1</gtr:description><gtr:id>C3DEDE2C-C93F-4091-A207-2DD8CE40CBCB</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>gB1ZVKmX7DK-1</gtr:outcomeId><gtr:partnerContribution>Identification of novel CDPK1 inhibnitors</gtr:partnerContribution><gtr:piContribution>Discovery of new PfCDPK1</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MC2</gtr:description><gtr:id>B757F70D-E4E9-49E3-9156-0C7E2AA34704</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>WvFV7GSiccq-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents</gtr:partnerContribution><gtr:piContribution>Drug discovery expertise, assay development and screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MCR2</gtr:description><gtr:id>710C87B7-DCBB-4C9C-90FB-3290C9728228</gtr:id><gtr:impact>Identification of novel small molecule ligands</gtr:impact><gtr:outcomeId>5461d68becfb22.62990667-1</gtr:outcomeId><gtr:partnerContribution>Biology expertise</gtr:partnerContribution><gtr:piContribution>Assay development, screening and medicinal chemistry</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Screening Libraries</gtr:description><gtr:id>04814D19-C0C7-45C1-AE98-930EB0016E44</gtr:id><gtr:impact>To date three targets has been selected for screening by AZ.

Multidisciplinary invoilving, biology, chemistry, pharmacology, ADME.</gtr:impact><gtr:outcomeId>j686NNfjue5-1</gtr:outcomeId><gtr:partnerContribution>Provision of 100,000 compounds in screening ready plates for screening versus up to 10 biochemical targets, 5 selected by AZ and 5 by MRCT.</gtr:partnerContribution><gtr:piContribution>Provision of screens and reagents plus personnel to run screens and validate hits</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>iC3b</gtr:description><gtr:id>38B95AB2-AA0D-4AEA-AD7B-5D7A6E5D6D1C</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>g7Es9UZHJH4-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents</gtr:partnerContribution><gtr:piContribution>Drug discovery capapability and expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>PAICS</gtr:description><gtr:id>DA214C4C-55DE-43FB-8149-26C33240505A</gtr:id><gtr:impact>Small molecule inhibitors</gtr:impact><gtr:outcomeId>56ddaa4268ffb8.13099342-1</gtr:outcomeId><gtr:partnerContribution>In vitro and in vivo testing</gtr:partnerContribution><gtr:piContribution>Screening and development of potent selective inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ERCC1</gtr:description><gtr:id>260C712D-7200-4019-BD3A-26798BE871A2</gtr:id><gtr:impact>Identification of hit molecules</gtr:impact><gtr:outcomeId>Akf2dyjrkNJ-1</gtr:outcomeId><gtr:partnerContribution>secondary assays and target validation</gtr:partnerContribution><gtr:piContribution>Screening and medicinal chemistry</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GPCR Deorphanisation</gtr:description><gtr:id>1AB56B1E-8370-4E9F-9809-A7927FA822D1</gtr:id><gtr:impact>Deorphanised GPCR 88 and 35. GPRR88 subject of succesful MJFF grant.</gtr:impact><gtr:outcomeId>PDwQinVDnHE-1</gtr:outcomeId><gtr:partnerContribution>Provision of ligand library and screening capabilityProvision of cell lines for screening</gtr:partnerContribution><gtr:piContribution>Screening and validation of hits versus 90 orphan GPCRS</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hong Kong</gtr:collaboratingOrganisation><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:description>EV71</gtr:description><gtr:id>BB4B3021-3CBD-4F84-BE44-48FA48C757F7</gtr:id><gtr:impact>Antibody for partnering</gtr:impact><gtr:outcomeId>56dda980df0331.61620130-1</gtr:outcomeId><gtr:partnerContribution>In vitro and in vivo testing</gtr:partnerContribution><gtr:piContribution>Humanisation and optimisation of antibody</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PfPKG</gtr:description><gtr:id>E05E1451-EE7A-4533-BDB3-1605CCAFB546</gtr:id><gtr:impact>Publications and patent</gtr:impact><gtr:outcomeId>TUrAg1vayoL-1</gtr:outcomeId><gtr:partnerContribution>Provision of in vitro and in vivo testing</gtr:partnerContribution><gtr:piContribution>DIscovery of novel small molecule inhibitors of PfPKG</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>CCR2</gtr:description><gtr:id>D4D2B6E5-7EB2-4138-A53F-01FEDE60E91D</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>WQcf4w38rZn-1</gtr:outcomeId><gtr:partnerContribution>Provision of mouse antibodies and assays</gtr:partnerContribution><gtr:piContribution>Humanisation of antibodies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Laval</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>C5L2/Asp1</gtr:description><gtr:id>CA7F9F74-8C7E-486E-8175-481F6974B0F0</gtr:id><gtr:impact>Antibody humanisation</gtr:impact><gtr:outcomeId>QYg7eiVkj8Y-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents</gtr:partnerContribution><gtr:piContribution>Antibody generation and humanisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Nicastrin</gtr:description><gtr:id>6AFB6131-7C4D-4112-86A9-1E44C19B3299</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>jLrTptAdV53-1</gtr:outcomeId><gtr:partnerContribution>Antibody generation</gtr:partnerContribution><gtr:piContribution>Antibody humanisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Georgetown University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ALK</gtr:description><gtr:id>F9824E4C-C443-43A2-BADB-729EB65C7FF3</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>pEiLNasadxb-1</gtr:outcomeId><gtr:partnerContribution>Antibody generation</gtr:partnerContribution><gtr:piContribution>Antibody humanisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lausanne</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>MALT1</gtr:description><gtr:id>1275DFD1-AF0F-482B-9387-D3FF193A5277</gtr:id><gtr:impact>Development of HTS assay</gtr:impact><gtr:outcomeId>5461d614aa99e0.87930711-1</gtr:outcomeId><gtr:partnerContribution>Biology expertise</gtr:partnerContribution><gtr:piContribution>Assay development and screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GalR2-ADC</gtr:description><gtr:id>CAA2EB1C-3F33-40C0-A234-D29264921F0A</gtr:id><gtr:impact>Generation of novel GalR2 based ADC</gtr:impact><gtr:outcomeId>5461d5ac363547.42481420-1</gtr:outcomeId><gtr:partnerContribution>Biology expertise</gtr:partnerContribution><gtr:piContribution>Generation of GalR2 antibody drug conjugate</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel anti-cancer agents</gtr:description><gtr:id>7BC0F038-FC4F-4A41-AF80-2B139566713E</gtr:id><gtr:impact>This programme has directly produced a collaboration with AZ (see Screening Compounds collaboration). Screening is ongoing to identify plausible hits for drug discovery.

Multidisciplinary invoilving, biology, chemistry, pharmacology, ADME.</gtr:impact><gtr:outcomeId>TDBsQYr1iEs-1</gtr:outcomeId><gtr:partnerContribution>Our collaborator has brought a wealth of expertise and relevant knowledge to the porogramme as well as direct experience of the target in question and he is an opinion leader in his field.</gtr:partnerContribution><gtr:piContribution>Provision of assay development, screening and chemistry resources to support a drug discovery programme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intellect Neurosciences, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Anti-amyoid (AD) antibody humanisation</gtr:description><gtr:id>A14CBFFF-6189-455A-B6DA-EA37E5FC2B2E</gtr:id><gtr:impact>Antibodies humanised succesfully</gtr:impact><gtr:outcomeId>nkeSMP3QgKo-1</gtr:outcomeId><gtr:piContribution>Humanisation and optimisation of antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beatson Institute for Cancer Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Fascin</gtr:description><gtr:id>AECCDE57-6079-406B-9A51-14694D346653</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>Ea8Hqoz4kWp-1</gtr:outcomeId><gtr:partnerContribution>Fragment screening and supporting biology</gtr:partnerContribution><gtr:piContribution>HTS screening versus target, hit validation and medicinal chemistry</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>FPR2</gtr:description><gtr:id>FA515E2C-5A0A-4DED-BEBF-22D990AB61B5</gtr:id><gtr:impact>Assays developed. Full drug discovery collaboration - biology, chemistry, pharmacology</gtr:impact><gtr:outcomeId>iBRdDxAMpsn-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents</gtr:partnerContribution><gtr:piContribution>Assay development and screening.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel Anti-malarial agents</gtr:description><gtr:id>D76CAABE-4166-472E-81A8-EA59C075B2A9</gtr:id><gtr:impact>Successful DPFS grant application. Multidisciplinary invoilving, biology, chemistry, pharmacology, ADME.</gtr:impact><gtr:outcomeId>ajzndxnNE9q-1</gtr:outcomeId><gtr:partnerContribution>The collaborator is an expert in his field and has in depth knowledge of the target as well as secondary assays to support a drug discovery programme.

Note that the &amp;pound;525,000 finacial contribution is from a succesful DPFS application. This will be offset against the &amp;pound;5m grant.</gtr:partnerContribution><gtr:piContribution>Assay development, screening and medicinal chemistry to support a drug discovery programme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MNK1</gtr:description><gtr:id>52609889-FB76-4C5A-908E-328DD61D3495</gtr:id><gtr:impact>Research collaboration</gtr:impact><gtr:outcomeId>RZrqxpExYKC-1</gtr:outcomeId><gtr:partnerContribution>Secondary assays and phrmacology</gtr:partnerContribution><gtr:piContribution>Medicinal chemistry and primary screening</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>DiscoveRx</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>GPCR Deorphanisation</gtr:description><gtr:id>F571A470-0992-4750-B15F-234752C74B85</gtr:id><gtr:impact>Deorphanised GPCR 88 and 35. GPRR88 subject of succesful MJFF grant.</gtr:impact><gtr:outcomeId>PDwQinVDnHE-2</gtr:outcomeId><gtr:partnerContribution>Provision of ligand library and screening capabilityProvision of cell lines for screening</gtr:partnerContribution><gtr:piContribution>Screening and validation of hits versus 90 orphan GPCRS</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (USA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IL-16</gtr:description><gtr:id>67AD4E3D-7CDC-476F-97EC-277E0CDC5287</gtr:id><gtr:impact>Publication and poster</gtr:impact><gtr:outcomeId>AohLeaM2FGU-1</gtr:outcomeId><gtr:partnerContribution>antibody generation</gtr:partnerContribution><gtr:piContribution>Antibody humnisation</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel anti-bacterial compounds</gtr:description><gtr:id>8FE3AF1B-85DA-4F89-96A4-B862370C973E</gtr:id><gtr:impact>DPFS application - invited to Full Application which has yet to be reviewed by the Panel.

Multidisciplinary involving biology, chemistry, pharmacology and ADME</gtr:impact><gtr:outcomeId>Mnoztq5gMbm-1</gtr:outcomeId><gtr:partnerContribution>Provision of protein production and crystallography. Expert knowledge of target - experts in the field. Secondary assays.</gtr:partnerContribution><gtr:piContribution>Assay development, screening and medicinal chemistry for a full drug discovery programme.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>PAICS</gtr:description><gtr:id>9D1C17C6-43DC-434C-AEC6-681690A71FB3</gtr:id><gtr:impact>Hit structures for optimisation</gtr:impact><gtr:outcomeId>YXA3xs7JHgB-1</gtr:outcomeId><gtr:partnerContribution>Secondary assays and target validation</gtr:partnerContribution><gtr:piContribution>Screening and medicinal chemistry</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Integrin alpha v beta 6</gtr:description><gtr:id>B2A33DCC-F45B-4C05-9A64-F9D251880021</gtr:id><gtr:impact>Humanised antibody for partnering</gtr:impact><gtr:outcomeId>SqbjMrBCfJY-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents</gtr:partnerContribution><gtr:piContribution>Antibody generation and humanisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MC3</gtr:description><gtr:id>21034B13-45A3-488A-B11A-D1623235D146</gtr:id><gtr:impact>ID of novel chemical series which were partnered with a major Pharma company</gtr:impact><gtr:outcomeId>L1DUG9AcCws-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents</gtr:partnerContribution><gtr:piContribution>Assay development, screening and small molecule ligand ID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Transglutaminase 2</gtr:description><gtr:id>5979919F-91E6-483A-B4F8-1DA290603C35</gtr:id><gtr:impact>We have partnered the project and a potential drug to a major Pharma company. The asset has just completed Ph I studies.</gtr:impact><gtr:outcomeId>TWXkpXDMke5-1</gtr:outcomeId><gtr:partnerContribution>EXpertise and reagents</gtr:partnerContribution><gtr:piContribution>Drug discovery, assay development, screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>APP/beta secretase</gtr:description><gtr:id>76D9FC4D-CD0D-47B7-B4C9-709B662D02D4</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>bXy5dzGqhjL-1</gtr:outcomeId><gtr:partnerContribution>Assays and reagents</gtr:partnerContribution><gtr:piContribution>Antibody generation and humanisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ELRIG conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>082D14FA-C39F-412F-BBCF-50FE1AC9D692</gtr:id><gtr:impact>Conference talk</gtr:impact><gtr:outcomeId>56ddacb592bc43.67883723</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Eisai Pharma</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A07A0F7B-E2F7-46C9-8DEF-FA8D4C104FDE</gtr:id><gtr:impact>Talk to six senior executives fro Eisai

Desire by Eisai to work with MRCT on new targets</gtr:impact><gtr:outcomeId>eJJgd5SHmig</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Miptech Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1594217B-75FD-4C06-86C6-081B5A03212C</gtr:id><gtr:impact>Over 200 people attended

Requests for more information</gtr:impact><gtr:outcomeId>TtGjVN4jHuJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SBS conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>69262EEF-6F08-4E31-93B0-2335A68132FE</gtr:id><gtr:impact>talk in front of several hundred pharma, biotech and academic scientists

More approaches to MRCT about collaborations</gtr:impact><gtr:outcomeId>SpZ1ULtLpCL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Global Alliance on Drug Discovery</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A76950C2-4DC9-4C8F-AE16-5733B2E216F4</gtr:id><gtr:impact>Awareness of drug discovery respource for academics worldwide

Approaches by academics to access resource and work with Alliance</gtr:impact><gtr:outcomeId>f2CdM7MohJM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dementia consortium</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5264FB55-1642-4162-A368-9F04CB403FC7</gtr:id><gtr:impact>Interviews resulted in articles in the Guardian and Times newspapers

Sparked other press agencies contacting us for quotes and input.</gtr:impact><gtr:outcomeId>5461db6f3762a3.93072943</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AstraZeneca</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>74766F8D-477D-4A18-B546-B53C4C50DF9D</gtr:id><gtr:impact>Talk to senior executives.

Signing of compound screening agreement</gtr:impact><gtr:outcomeId>cs2rPFsuQ8C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Crowd Sourcing Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F7ED00C3-C080-49C6-B43A-E108C672270B</gtr:id><gtr:impact>Invited audience of 150 delegates

Requests for more information</gtr:impact><gtr:outcomeId>iczLbPV1mmU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GSK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>107C6C32-1ABD-4E42-871D-47C81ADC9DE8</gtr:id><gtr:impact>Presentation on output from GPCR de-orphainsation programme

Interest from GSK in further collaborations and in-licencing</gtr:impact><gtr:outcomeId>ct6kXrrK1Gv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Michael J Fox Foundation</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>56C39EC2-5AFE-4937-A916-6814C2DCBCC3</gtr:id><gtr:outcomeId>GoeEqpcq5ZA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>525000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F9B1246A-83A9-47BE-A4BB-FBDA7A61183E</gtr:id><gtr:outcomeId>csZLyqqGF2R0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>587000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biomedical Catalyst</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>730F487D-ED80-455D-937C-6611FF51F06B</gtr:id><gtr:outcomeId>GJ5mTMtCKCW</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A7138DA2-E43B-4097-8060-61116B4DF020</gtr:id><gtr:outcomeId>KimtuzGrcQh0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Humanized anti-CD20 antibodies</gtr:description><gtr:grantRef>MC_G1000806</gtr:grantRef><gtr:id>365F2C78-DDCD-45E9-99A3-DAC5B9BE1BFE</gtr:id><gtr:impact>New antibodies for treating disease</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>ePLFgwWWKN5</gtr:outcomeId><gtr:patentId>WO2010080528</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Humanized anti-CD20 antibodies</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>pyrazolopyridine compounds as kinase inhibitors</gtr:description><gtr:grantRef>MC_G1000806</gtr:grantRef><gtr:id>9FEB60F2-A4A3-4BEE-8A36-62B709DBB812</gtr:id><gtr:impact>First known selective inhibitor of this kinase</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>hehRZVWJHke</gtr:outcomeId><gtr:patentId>WO2010106333</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Preparation of pyrazolopyridine compounds as kinase inhibitors.</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Identification of novel small molecule ligands</gtr:description><gtr:grantRef>MC_G1000806</gtr:grantRef><gtr:id>B5422CA9-6D88-4960-9144-8E3705F8CD53</gtr:id><gtr:impact>Identification of novel small molecule ligands to support candidate seeking programme</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>5461d8278c40f3.91526011</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>MC3</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>pyrimidine derivatives capable of inhibiting one or more kinases</gtr:description><gtr:grantRef>MC_G1000806</gtr:grantRef><gtr:id>8319A695-1992-4145-9F06-C7A7D6CFEA19</gtr:id><gtr:impact>Selective tool compounds for disease association studies</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>anyqQHYFYmq</gtr:outcomeId><gtr:patentId>WO2009122180</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Preparation of pyrimidine derivatives capable of inhibiting one or more kinases</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Identification of novel TG2 humanised antibody</gtr:description><gtr:grantRef>MC_G1000806</gtr:grantRef><gtr:id>D45ED8C1-B971-4336-942B-84DAB6CD1076</gtr:id><gtr:impact>Expansion of scientific knowledge and preclinical candidate licensed</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>5461d7e70017c8.77632529</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>TG2</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>pyrrolopyrimidines as kinase inhibitors</gtr:description><gtr:grantRef>MC_G1000806</gtr:grantRef><gtr:id>F491EEB3-82EA-42AD-85DE-903B4FD79871</gtr:id><gtr:impact>Highly selective inhibitors as tool compounds for disease association</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>imJYo4WjbfC</gtr:outcomeId><gtr:patentId>WO2010100431</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Preparation of pyrrolopyrimidines as kinase inhibitors</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>TG2 antibody for fibrosis</gtr:description><gtr:id>5FF820D5-BCE4-466E-A1DF-F5EDE25052B4</gtr:id><gtr:impact>Novel approach to treating pulmonary fibrosis</gtr:impact><gtr:outcomeId>F72FQijKK13</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TG2</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>alphavbeta6 humanised antibody</gtr:description><gtr:id>18C54D1E-32D2-437A-A1BA-B014251B3F6E</gtr:id><gtr:impact>Potential new drug</gtr:impact><gtr:outcomeId>kLx4pqU4oNZ</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>alphavbeta6</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Small molecule ligands</gtr:description><gtr:id>B6338A2F-A686-4135-A1A1-CB358F9A5909</gtr:id><gtr:impact>New tools made available</gtr:impact><gtr:outcomeId>56ddab7a7f1053.23071910</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MCR3</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Alphavbeta6 humanised antibody</gtr:description><gtr:id>041E06EA-613D-47CA-ADED-7236CC281FF9</gtr:id><gtr:impact>Potential partnering event</gtr:impact><gtr:outcomeId>FaaypYHn5JT</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Alphavbeta6</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Six different PROKR1 antagonists were made from literature exaples</gtr:description><gtr:id>F39BB6DB-6EEE-4FDC-A95A-ABAB8D91F043</gtr:id><gtr:impact>Used for target validationa dn diseae association. Work is ongoing but initial results look to be linking PROKR1 to a specific disease of interest.</gtr:impact><gtr:outcomeId>iMPsfFxnPVY</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PROKR1 antagonists</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Biotinylated guanabenz</gtr:description><gtr:id>E0EDDA82-61B4-4F8A-B222-45BB771D1EA3</gtr:id><gtr:impact>Used for target identification and association. Results pending</gtr:impact><gtr:outcomeId>FBxut49bYVw</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Biotinylated guanabenz</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Two literature FPR2 agonists</gtr:description><gtr:id>EE5293CB-7722-476F-8A68-CB34D3A86D0F</gtr:id><gtr:impact>Target validation and disease association - ongoing</gtr:impact><gtr:outcomeId>LdcoUvjtY16</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>FPR2 agonist</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PNKP inhibitor published by Weinfeld et al.</gtr:description><gtr:id>D7FE736E-9035-4231-AF43-097DE3CB34C9</gtr:id><gtr:impact>Used to see if it was a good inhibitor of PNKP and for mechanistic studies. Our research identified it is not a very good inhibitor and is non-selective, hitting a wide range of kinases from the PPU panel.</gtr:impact><gtr:outcomeId>U6Kd9eqL1yc</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PNKP Weinfeld compound</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Migrastatin analogues</gtr:description><gtr:id>07876040-2728-41AD-9C95-2019688FE588</gtr:id><gtr:impact>Target validation and disease association. Results pending</gtr:impact><gtr:outcomeId>hZLyRh2rnQQ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Migrastatin analogues</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Three literature Gpr35 antagonists</gtr:description><gtr:id>717022CD-E545-4FD7-887A-47138CFC2F00</gtr:id><gtr:impact>Used for disease association, results pending.</gtr:impact><gtr:outcomeId>ctbC6GKZgmJ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Gpr35 antagonists</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Two literature MurC compounds</gtr:description><gtr:id>4856AEB0-9829-4F56-AD88-25B55FF3DDB7</gtr:id><gtr:impact>Target validation and co-crystallisation studies - ongoing</gtr:impact><gtr:outcomeId>gNE5ZJ3s67i</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MurC compounds</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Small molecule ligands</gtr:description><gtr:id>800C51E2-555C-4050-974C-FB8ADE4B5893</gtr:id><gtr:impact>Publications and further disection of pathway</gtr:impact><gtr:outcomeId>5461dc862ad941.94461555</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CDPK1</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Literature NK1 antagonist</gtr:description><gtr:id>5E3B6D04-B31F-42E4-9F2E-67090BA02604</gtr:id><gtr:impact>Material used for pathway validation. Results pending</gtr:impact><gtr:outcomeId>ZNW73XWNCwq</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NK1 agonist</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Humanised antibody</gtr:description><gtr:id>48990754-07B0-42D0-930A-3E3054529F50</gtr:id><gtr:impact>Potential partnering event</gtr:impact><gtr:outcomeId>pZfa6g7FEXJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CCR2</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Two PfPKG inhibitors provided</gtr:description><gtr:id>638009AD-4600-42CB-89E3-545924C1FF3F</gtr:id><gtr:impact>Target validation - ongoing</gtr:impact><gtr:outcomeId>UpgX3VWFpUB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PKG compounds</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>607C8F84-8F38-41EB-81DC-E2BAF6969742</gtr:id><gtr:title>Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbd5fc47723096b3e0f2a3c6fbdc73b2"><gtr:id>fbd5fc47723096b3e0f2a3c6fbdc73b2</gtr:id><gtr:otherNames>McMahon RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>b6ec8rTNJpu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C85EA9CD-6D3B-4D9D-9DE8-4B9B3BCD7D6E</gtr:id><gtr:title>A high-throughput assay for modulators of NNT activity in permeabilized yeast cells.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular screening</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80430d558dca4f4d1f3a3dafd51da870"><gtr:id>80430d558dca4f4d1f3a3dafd51da870</gtr:id><gtr:otherNames>Meadows NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0571</gtr:issn><gtr:outcomeId>YmxXx1d58Kp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50C7E500-D427-49D7-AF6D-459AF69AA93A</gtr:id><gtr:title>Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f0d2f0a76db496f8a5fbca8cdbc3d0"><gtr:id>e0f0d2f0a76db496f8a5fbca8cdbc3d0</gtr:id><gtr:otherNames>Chapman TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>56dda8189374e3.35967557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E157E760-3133-498D-9E61-739B4A306FAD</gtr:id><gtr:title>The role of TBK1 and IKKe in the expression and activation of Pellino 1.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7617b24e424e111cf0ed36e041ad9d1"><gtr:id>e7617b24e424e111cf0ed36e041ad9d1</gtr:id><gtr:otherNames>Smith H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>emfsS1iRJVd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26992C89-91FE-42B6-83A4-B5C8D203F574</gtr:id><gtr:title>Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9992c8acc664d8a4cf35bcdfe307fbe"><gtr:id>b9992c8acc664d8a4cf35bcdfe307fbe</gtr:id><gtr:otherNames>Lougheed KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>SWd3EWY9V8g</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>643D2082-9EE4-4F3C-BBA8-DB1BC4EBF8CB</gtr:id><gtr:title>Antagonists of GPR35 display high species ortholog selectivity and varying modes of action.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20d6345de8224bf0931bf3965fdcdf6e"><gtr:id>20d6345de8224bf0931bf3965fdcdf6e</gtr:id><gtr:otherNames>Jenkins L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>pm_13848_28_22967846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A01088DD-F6BE-4793-BD0C-CA9C3A11BA62</gtr:id><gtr:title>Monocyclic ?-lactams are selective, mechanism-based inhibitors of rhomboid intramembrane proteases.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88522e1e5016adad37844bcf470b8205"><gtr:id>88522e1e5016adad37844bcf470b8205</gtr:id><gtr:otherNames>Pierrat OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>QFbkMvJhkSm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AF194FA-8029-41B4-9954-29A440E0A789</gtr:id><gtr:title>An intrinsically labile a-helix abutting the BCL9-binding site of ?-catenin is required for its inhibition by carnosic acid.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78fe2c32ff9eac9f043fa9730d79f513"><gtr:id>78fe2c32ff9eac9f043fa9730d79f513</gtr:id><gtr:otherNames>de la Roche M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13848_28_22353711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A494B9D-AC9B-4BB4-A6CF-BE1C2AB8E6F3</gtr:id><gtr:title>Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c255ff65577bfc91cef459008b7f3237"><gtr:id>c255ff65577bfc91cef459008b7f3237</gtr:id><gtr:otherNames>Guzman JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_13848_28_23794563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AEB5001-27BF-4EA3-9DD3-4373F58C4C31</gtr:id><gtr:title>Structure of rhomboid protease in complex with ?-lactam inhibitors defines the S2' cavity.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df5a2fdb0720651e9d64218b2f35521a"><gtr:id>df5a2fdb0720651e9d64218b2f35521a</gtr:id><gtr:otherNames>Vinothkumar KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>pm_13848_28_23665170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E287E542-A1FC-43A3-9880-6C4C1024C42E</gtr:id><gtr:title>Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad06962ecc8a6d299082b428da241483"><gtr:id>ad06962ecc8a6d299082b428da241483</gtr:id><gtr:otherNames>Goncalves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_13848_28_22439843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF9AEBC2-F301-463E-8FB4-FE20EC3A3AFB</gtr:id><gtr:title>Novel cross-talk within the IKK family controls innate immunity.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3af18b6a48e1cb8adf61b897c0097848"><gtr:id>3af18b6a48e1cb8adf61b897c0097848</gtr:id><gtr:otherNames>Clark K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>bZXZdERbcuN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4376E9A1-DFA6-4647-AA04-8CDA7641C811</gtr:id><gtr:title>Screening ?-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular screening</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baac39af21e9c15ce92930930c13bb55"><gtr:id>baac39af21e9c15ce92930930c13bb55</gtr:id><gtr:otherNames>Southern C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-0571</gtr:issn><gtr:outcomeId>pm_13848_28_23396314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CF7239F-2F21-443B-AAB6-2D52A737B4BB</gtr:id><gtr:title>Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16): MECHANISTIC INSIGHTS AND NEW THERAPEUTIC OPPORTUNITIES.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2cb9d33b71829c0f4584adb2871113"><gtr:id>8d2cb9d33b71829c0f4584adb2871113</gtr:id><gtr:otherNames>Hall G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>58b5484d926fc3.69348317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D1AC7E7-03C7-4FED-8C63-422220CA0FB9</gtr:id><gtr:title>Imidazopyridazine Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 Also Target Cyclic GMP-Dependent Protein Kinase and Heat Shock Protein 90 To Kill the Parasite at Different Stages of Intracellular Development.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53d6e471c849e174b17d32295691036"><gtr:id>b53d6e471c849e174b17d32295691036</gtr:id><gtr:otherNames>Green JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>56dda818b71f50.31760809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1118C103-1AD7-4F85-8E4E-A4E6F74E3272</gtr:id><gtr:title>Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f0d2f0a76db496f8a5fbca8cdbc3d0"><gtr:id>e0f0d2f0a76db496f8a5fbca8cdbc3d0</gtr:id><gtr:otherNames>Chapman TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_13848_28_22469702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61EC78B8-421B-4D4C-B5E7-5BAA924C6093</gtr:id><gtr:title>Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f0d2f0a76db496f8a5fbca8cdbc3d0"><gtr:id>e0f0d2f0a76db496f8a5fbca8cdbc3d0</gtr:id><gtr:otherNames>Chapman TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5461d29e9fdbb9.56719052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>052CF670-C77C-416C-BA2C-05846CF6FDB7</gtr:id><gtr:title>Identification of small-molecule inhibitors of the ribonuclease H2 enzyme.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular screening</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da8ffc29a5c3678e08a1a5f82204a9d2"><gtr:id>da8ffc29a5c3678e08a1a5f82204a9d2</gtr:id><gtr:otherNames>White R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-0571</gtr:issn><gtr:outcomeId>pm_13848_28_23427046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>287003A2-3B2C-4664-A709-37427195A30A</gtr:id><gtr:title>N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f0d2f0a76db496f8a5fbca8cdbc3d0"><gtr:id>e0f0d2f0a76db496f8a5fbca8cdbc3d0</gtr:id><gtr:otherNames>Chapman TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>56dda8191dfe27.14791689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFADE0CA-FAA2-4256-9988-F9CD0C096A9A</gtr:id><gtr:title>High-throughput identification and characterization of novel, species-selective GPR35 agonists.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9e68447e154638716b24695e1c9692b"><gtr:id>a9e68447e154638716b24695e1c9692b</gtr:id><gtr:otherNames>Neetoo-Isseljee Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>pm_13848_28_23262279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AD1AD43-26C3-43C2-B1C7-AD8A7A7B6EB3</gtr:id><gtr:title>A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92dc5244f0719d05597c9ae63e0413fc"><gtr:id>92dc5244f0719d05597c9ae63e0413fc</gtr:id><gtr:otherNames>Huart AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_13848_28_24007918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB17F32-18BF-44E9-B41B-77F1D7EF3931</gtr:id><gtr:title>A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular screening</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f25370e773daa986a5ae8aff6b6310c"><gtr:id>9f25370e773daa986a5ae8aff6b6310c</gtr:id><gtr:otherNames>Wright PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1087-0571</gtr:issn><gtr:outcomeId>56dda818d67731.09323976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD9BDEEE-CEFA-428D-95C4-D8246F7B5887</gtr:id><gtr:title>ACTH Antagonists.</gtr:title><gtr:parentPublicationTitle>Frontiers in endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1cc2aa8d2d6d1ed6ad73bf575ba1f1f"><gtr:id>f1cc2aa8d2d6d1ed6ad73bf575ba1f1f</gtr:id><gtr:otherNames>Clark AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-2392</gtr:issn><gtr:outcomeId>58b5484d62aa78.85960347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>615ED912-289B-4366-A79A-214E4E7CD315</gtr:id><gtr:title>Crowd sourcing in drug discovery.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0ee5d49bc6bdf646cd007f4271ec9da"><gtr:id>e0ee5d49bc6bdf646cd007f4271ec9da</gtr:id><gtr:otherNames>Lessl M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>Y1SmzxbaRCp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C9101F7-8CF4-497B-9785-4C8DD4A7F1D3</gtr:id><gtr:title>Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.</gtr:title><gtr:parentPublicationTitle>DNA repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c89e27f8f800bbe75e44d85ebdf0149e"><gtr:id>c89e27f8f800bbe75e44d85ebdf0149e</gtr:id><gtr:otherNames>McNeil EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1568-7856</gtr:issn><gtr:outcomeId>56dda818f25b66.64981638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3140B432-D8CA-4E6B-BEF9-9A4DA348AE3B</gtr:id><gtr:title>Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2717fe55f9cc7b096fe5000a6d5c180f"><gtr:id>2717fe55f9cc7b096fe5000a6d5c180f</gtr:id><gtr:otherNames>Large JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_13848_28_24035097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D2EABAA-5B27-4A49-8BAC-EA5E952F93D0</gtr:id><gtr:title>Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f0d2f0a76db496f8a5fbca8cdbc3d0"><gtr:id>e0f0d2f0a76db496f8a5fbca8cdbc3d0</gtr:id><gtr:otherNames>Chapman TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_13848_28_23570789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63763EE0-C37F-496B-86AC-4BBF628DC69E</gtr:id><gtr:title>Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c12da52bf60c62081ad5f615656e39f3"><gtr:id>c12da52bf60c62081ad5f615656e39f3</gtr:id><gtr:otherNames>Antonios G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56dda818723356.52171215</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1000806</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>